Jason Cole Sells 1,129 Shares of bluebird bio, Inc. (BLUE) Stock
bluebird bio, Inc. (NASDAQ:BLUE) insider Jason Cole sold 1,129 shares of bluebird bio stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $173.38, for a total transaction of $195,746.02. Following the transaction, the insider now owns 19,945 shares of the company’s stock, valued at approximately $3,458,064.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
bluebird bio, Inc. (NASDAQ:BLUE) opened at $171.95 on Thursday. The firm has a market cap of $7,880.00, a P/E ratio of -24.53 and a beta of 2.08. bluebird bio, Inc. has a 52-week low of $63.10 and a 52-week high of $222.03.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business’s quarterly revenue was up 397.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.07) EPS. research analysts anticipate that bluebird bio, Inc. will post -6.72 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. QS Investors LLC grew its holdings in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its holdings in bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares during the period. Biondo Investment Advisors LLC purchased a new stake in bluebird bio in the third quarter valued at approximately $203,000. SG Americas Securities LLC grew its holdings in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares during the period. Finally, Fairfield Bush & CO. purchased a new stake in bluebird bio in the second quarter valued at approximately $210,000.
BLUE has been the subject of a number of research reports. Goldman Sachs Group restated a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Maxim Group restated a “buy” rating and set a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. BMO Capital Markets lifted their target price on shares of bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research report on Monday, October 30th. BTIG Research upgraded shares of bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 target price for the company in a research report on Thursday, November 2nd. Finally, SunTrust Banks lifted their target price on shares of bluebird bio from $108.00 to $163.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $157.45.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/11/jason-cole-sells-1129-shares-of-bluebird-bio-inc-blue-stock.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.